Submitted:
05 November 2024
Posted:
07 November 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Study Design, Participants and Data Collection
2.2. Measurements and Methods
2.3. Data Analysis
3. Results
3.1. Two Samples Comparisons and Analysis of Variance for Serum Leptin, TNF-α, IL-6, Cholesterol, Testosterone and Other Variables in Hypertensive and Overweight-Related Hypertensive Men
3.2. Association of Serum Leptin with Other Variables in Hypertensive and Overweight-Related Hypertensive Men
3.3. Association of Serum TNF-alpha with Other Variables in Hypertensive and Overweight-Related Hypertensive Men
3.4. Association of Serum Testosterone with Other Variables in Hypertensive and Overweight-Related Hypertensive Men
3.5. Association of Serum Interleukin-6 with Other Variables in Hypertensive and Overweight-Related Hypertensive Men
3.6. Association of Total Cholesterol with Other Variables in Hypertensive and Overweight-related Hypertensive Men
4. Discussion
5. Limitations
List of Abbreviations
| ANOVA | Analysis of variance |
| BMI | Body mass index |
| BP | Blood pressure |
| BW | Body weight |
| CHD | Coronary heart disease |
| CVD | Cardiovascular disease |
| DBP | Diastolic blood pressure |
| DM | Diabetes mellitus |
| ELISA | Enzyme-linked immunosorbent assay |
| FBG | Fasting blood glucose |
| hCG | Human chorionic gonadotropin |
| HNW | High normal weight |
| HOW | High overweight |
| Hp | Hepcidin |
| HT | Hypertension/ hypertensive |
| IL-6 | Interleukin-6 |
| Lep | Leptin |
| LH | Luteinizing hormone |
| LNW | Low normal weight |
| LOW | Low overweight |
| MNW | Medium normal weight |
| MOW | Medium overweight |
| n | Number of subjects/samples |
| NC | Normal control/controls |
| NHT | Non-hypertensive |
| NO | Nitric oxide |
| NT | Normotensive/ normotensives |
| NW | Normal weight |
| OHT | Overweight hypertensive/ hypertensives |
| OW | Overweight |
| PVAT | Perivascular adipose tissue |
| ROS | Radical oxygen species |
| SBP | Systolic blood pressure |
| SD | Standard deviation |
| ST | Serum testosterone |
| TC | Total cholesterol |
| TNF-α | Tumor necrosis factor-alpha |
| TPE | Therapeutic patient education |
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgement
Conflicts of Interest
Consent for Publication
References
- Kearney, P.M.; Whelton, M.; Reynolds, K.; Muntner, P.; Whelton, P.K.; He, J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005, 365, 217–223. [Google Scholar] [CrossRef] [PubMed]
- Jaacks, L.M.; Vandevijvere, S.; Pan, A.; McGowan, C.J.; Wallace, C.; Imamura, F.; Mozaffarian, D.; Swinburn, B.; Ezzati, M. The obesity transition: stages of the global epidemic. Lancet Diabetes Endocrinol. 2019, 7, 231–240. [Google Scholar] [CrossRef] [PubMed]
- Fantin, F.; Giani, A.; Zoico, E.; Rossi, AP.; Mazzali, G.; Zamboni, M. Weight Loss and Hypertension in Obese Subjects. Nutrients. 2019, 11, 1667. [Google Scholar] [CrossRef] [PubMed]
- Wilson, P.W.; D’Agostino, R.B.; Sullivan, L.; Parise, H.; Kannel, W.B. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002, 162, 1867–1872. [Google Scholar] [CrossRef]
- Linhart, C.; Tukana, I.; Lin, S.; Taylor, R.; Morrell, S.; Vatucawaqa, P.; Magliano, D.; Zimmet, P. Continued increases in hypertension over three decades in Fiji, and the influence of obesity. J Hypertens. 2016, 34, 402–409. [Google Scholar] [CrossRef]
- Kannel, W.B. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA. 1996, 275, 1571–1576. [Google Scholar] [CrossRef]
- Hubert, H.B.; Feinleib, M.; McNamara, P.M.; Castelli, W.P. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983, 67, 968–977. [Google Scholar] [CrossRef]
- Zhu, L.; Fang, Z.; Jin, Y.; Chang, W.; Huang, M.; Chen, Y.; Yao, Y. Circulating ERBB3 levels are inversely associated with the risk of overweight-related hypertension: a cross-sectional study. BMC Endocr Disord. 2021, 21, 130. [Google Scholar] [CrossRef]
- Cutler, J.A.; Sorlie, P.D.; Wolz, M.; Thom, T.; Fields, L.E.; Roccella, E.J. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988–1994 and 1999–2004. Hypertension. 2008, 52, 818–827. [Google Scholar] [CrossRef]
- Bramlage, P.; Pittrow, D.; Wittchen, H.U.; Kirch, W.; Boehler, S.; Lehnert, H.; Hoefler, M.; Unger, T.; Sharma, A.M. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens. 2004, 17, :904–910. [Google Scholar] [CrossRef]
- NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants. Lancet. 2017, 389, 37–55. [Google Scholar] [CrossRef] [PubMed]
- Shihab, H.M.; Meoni, L.A.; Chu, A.Y.; Wang, N.Y.; Ford, D.E.; Liang, K.Y.; Gallo, J.J.; Klag, M.J. Body mass index and risk of incident hypertension over the life course: the Johns Hopkins Precursors Study. Circulation. 2012, 126, 2983–2989. [Google Scholar] [CrossRef] [PubMed]
- Williams, B.; Mancia, G.; Spiering, W.; Agabiti Rosei, E.; Azizi, M.; Burnier, M.; Clement, D.L.; Coca, A.; de Simone, G.; Dominiczak, A.; et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018, 39, 3021–3104. [Google Scholar] [CrossRef]
- Higashino, R.; Miyaki, A.; Kumagai, H.; Choi, Y.; Akazawa, N.; Ra, S.G.; Tanabe, Y.; Eto, M.; So, R.; Tanaka, K.; et al. Effects of lifestyle modification on central blood pressure in overweight and obese men. Blood Press Monit. 2013, 18, 311–315. [Google Scholar] [CrossRef] [PubMed]
- Ho, A.K.; Bartels, C.M.; Thorpe, C.T.; Pandhi, N.; Smith, M.A.; Johnson, H.M. Achieving Weight Loss and Hypertension Control Among Obese Adults: A US Multidisciplinary Group Practice Observational Study. Am J Hypertens. 2016, 29, 984–991. [Google Scholar] [CrossRef]
- Whelton, P.K.; Carey, R.M.; Aronow, WS.; Casey, D.E. Jr.; Collins, K.J.; Dennison Himmelfarb, C.; DePalma, S.M.; Gidding, S.; Jamerson, K.A.; Jones, D.W.; et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018, 71, e127–e248. [Google Scholar]
- Lechi, A. The obesity paradox: is it really a paradox? Hypertension. Eat Weight Disord. 2017, 22, 43–48. [Google Scholar] [CrossRef]
- Pouvreau, C.; Dayre, A.; Butkowski, E.G.; de Jong, B.; Jelinek, H.F. Inflammation and oxidative stress markers in diabetes and hypertension. J Inflamm Res. 2018, 11, 61–68. [Google Scholar] [CrossRef]
- Aminuddin, A.; Salamt, N.; Ahmad Fuad, A.F.; Chin, K.Y.; Ugusman, A.; Soelaiman, I.N.; Wan Ngah, W.Z. Vascular Dysfunction among Malaysian Men with Increased BMI: An Indication of Synergistic Effect of Free Testosterone and Inflammation. Medicina (Kaunas). 2019, 55, 575. [Google Scholar] [CrossRef]
- Wu, Y.; Xu, D.; Shen, H.B.; Qian, S.B.; Qi, J.; Sheng, X.J. The association between body mass index and testosterone deficiency in aging Chinese men with benign prostatic hyperplasia: results from a cross-sectional study. Aging Male. 2019. [CrossRef]
- Daiber, A.; Steven, S.; Weber, A.; Shuvaev, V.V.; Muzykantov, V.R.; Laher, I.; Li, H.; Lamas, S.; Münzel, T. Targeting vascular (endothelial) dysfunction. Br J Pharmacol. 2017, 174, 1591–1619. [Google Scholar] [CrossRef] [PubMed]
- Grossmann, M. Hypogonadism and male obesity: focus on unresolved questions. Clin Endocrinol. (Oxf) 2018, 89, 11–21. [Google Scholar] [CrossRef] [PubMed]
- Gonçalves, C.V.; Ribeiro, I.S.; Galantini, M.P.L.; Muniz, I.P.R.; Lima, P.H.B.; Santos, G.S.; da Silva, R.A.A. Inflammaging and body composition: New insights in diabetic and hypertensive elderly men. Exp Gerontol. 2022, 170, 112005. [Google Scholar] [CrossRef] [PubMed]
- Wong, C.Y.; Byrne, N.M.; O'Moore-Sullivan, T.; Hills, A.P.; Prins, J.B.; Marwick, T.H. Effect of weight loss due to lifestyle intervention on subclinical cardiovascular dysfunction in obesity (body mass index >30 kg/m2). Am J Cardiol. 2006, 98, 1593–1598. [Google Scholar] [CrossRef] [PubMed]
- Phillips, C.L.; Yee, B.J.; Trenell, M.I.; Magnussen, J.S.; Wang, D.; Banerjee, D.; Berend, N.; Grunstein, R.R. Changes in regional adiposity and cardio-metabolic function following a weight loss program with sibutramine in obese men with obstructive sleep apnea. J Clin Sleep Med. 2009, 5, 416–421. [Google Scholar] [CrossRef]
- Alaamri, S.; Serafi, A.S.; Hussain, Z.; Alrooqi, M.M.; Bafail, M.A.; Sohail, S. Blood Pressure Correlates with Serum Leptin and Body Mass Index in Overweight Male Saudi Students. J Pers Med. 2023, 13, 828. [Google Scholar] [CrossRef]
- Keys, A.; Fidanza, F.; Karvonen, M.J.; Kimura, N.; Taylor, H.L. Indices of relative weight and obesity. J. Chronic Dis. 1972, 25, 329–343. [Google Scholar] [CrossRef]
- Shah, N.R.; Braverman, E.R. Measuring adiposity in patients: the utility of body mass index (BMI), percent body fat, and leptin. PLoS One 2012, 7, e33308. [Google Scholar] [CrossRef]
- Harakeh, S.; Kalamegam, G.; Pushparaj, P.N.; Al-Hejin, A.; Alfadul, S.M.; Al Amri, T.; Barnawi, S.; Al Sadoun, H.; Mirza, A.A.; Azhar, E. Chemokines and their association with body mass index among healthy Saudis. Saudi J Biol Sci. 2020, 7, 6–11. [Google Scholar] [CrossRef]
- Oh, S.Y.; Ryue, J.; Hsieh, C.H.; Bell, D.E. Eggs enriched in omega-3 fatty acids and alterations in lipid concentrations in plasma and lipoproteins and in blood pressure. Am J Clin Nutr. 1991, 54, 689–695. [Google Scholar] [CrossRef]
- Basile, J.N. Rationale for fixed-dose combination therapy to reach lower blood pressure goals. South Med J. 2008, 101, 918–924. [Google Scholar] [CrossRef] [PubMed]
- de Faria, A.P.; Modolo, R.; Fontana, V.; Moreno, H. Adipokines: novel players in resistant hypertension. J Clin Hypertens. (Greenwich) 2014, 16, 754–59. [Google Scholar] [CrossRef] [PubMed]
- Zahir, H.; Javaid, A.; Rehman, R.; Hussain, Z. Statistical concepts in biology and health sciences. J. Ayub Med Coll Abbottabad. 2014, 26, 95–97. [Google Scholar]
- Seven, E. Overweight, hypertension and cardiovascular disease: focus on adipocytokines, insulin, weight changes and natriuretic peptides. Dan Med J. 2015, 62, B5163. [Google Scholar] [PubMed]
- Zachariah, J.P.; Hwang, S.; Hamburg, N.M.; Benjamin, E.J.; Larson, M.G.; Levy, D.; Vita, J.A.; Sullivan, L.M.; Mitchell, G.F.; Vasan, R.S. Circulating Adipokines and Vascular Function: Cross-Sectional Associations in a Community-Based Cohort. Hypertension. 2016, 67, 294–300. [Google Scholar] [CrossRef] [PubMed]
- Zanoli, L.; Di Pino, A.; Terranova, V.; Di Marca, S.; Pisano, M.; Di Quattro, R.; Ferrara, V.; Scicali, R.; Rabuazzo, A.M.; Fatuzzo, P.; et al. Inflammation and ventricular-vascular coupling in hypertensive patients with metabolic syndrome. Nutr Metab Cardiovasc Dis. 2018, 28, 1222–1229. [Google Scholar] [CrossRef]
- Fernández-Alfonso, M.S.; Gil-Ortega, M.; García-Prieto, C.F.; Aranguez, I.; Ruiz-Gayo, M.; Somoza, B. Mechanisms of perivascular adipose tissue dysfunction in obesity. Int J Endocrinol. 2013, 2013, 402053. [Google Scholar] [CrossRef]
- Szasz, T.; Bomfim, G.F.; Webb, R.C. The influence of perivascular adipose tissue on vascular homeostasis. Vasc Health Risk Manag. 2013, 9, 105–116. [Google Scholar] [CrossRef]
- Purdham, D.M.; Zou, M.X.; Rajapurohitam, V.; Karmazyn, M. Rat heart is a site of leptin production and action. Am J Physiol Heart Circ Physiol. 2004, 287, H2877–H2884. [Google Scholar] [CrossRef]
- Parhami, F.; Tintut, Y.; Ballard, A.; Fogelman, A.M. ; Demer. L.L. Leptin enhances the calcification of vascular cells: artery wall as a target of leptin. Circ Res. 2001, 88, 954–960. [Google Scholar]
- Werner, N.; Nickenig, G. From fat fighter to risk factor: the zigzag trek of leptin. Arterioscler Thromb Vasc Biol. 2004, 24, 7–9. [Google Scholar] [CrossRef] [PubMed]
- Yamagishi, S.I.; Edelstein, D.; Du, X.L.; Kaneda, Y.; Guzmán. M.; Brownlee, M. Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem. 2001, 276, 25096–25100. [Google Scholar] [CrossRef] [PubMed]
- Catharina, AS.; Modolo, R.; Ritter, A.; Sabbatini, A.; Correa, N.; Brunelli, V.; Fraccaro, N.; Almeida, A.; Lopes, H.; Moreno, H.; De Faria, A. [PP.05.34] metabolic syndrome-related features in controlled and resistant hypertensive subjects. J. Hypertens. 2017, 35, e128. [Google Scholar] [CrossRef]
- Grassi, G.; Seravalle, G.; Brambilla, G.; Buzzi, S.; Volpe, M.; Cesana, F.; Dell'oro, R.; Mancia, G. Regional differences in sympathetic activation in lean and obese normotensive individuals with obstructive sleep apnoea. J Hypertens. 2014, 32, 383–388. [Google Scholar] [CrossRef] [PubMed]
- Grassi, G.; Mark, A.; Esler, M. The sympathetic nervous system alterations in human hypertension. Circ Res. 2015, 116, 976–990. [Google Scholar] [CrossRef]
- Grassi, G.; Pisano, A.; Bolignano, D.; Seravalle, G.; D'Arrigo, G.; Quarti-Trevano, F.; Mallamaci, F.; Zoccali, C.; Mancia, G. Sympathetic Nerve Traffic Activation in Essential Hypertension and Its Correlates: Systematic Reviews and Meta-Analyses. Hypertension. 2018, 72, 483–491. [Google Scholar] [CrossRef]
- Kaur, J.; Mukheja, S.; Varma, S.; Kalra, H.S.; Khosa, B.S.; Vohra, K. Serum progranulin/tumor necrosis factor-α ratio as independent predictor of systolic blood pressure in overweight hypertensive patients: a cross-sectional study. Egypt Heart J. 2020, 72, 25. [Google Scholar] [CrossRef]
- Virdis, A.; Dell'Agnello, U.; Taddei, S. Impact of inflammation on vascular disease in hypertension. Maturitas. 2014, 78, 179–183. [Google Scholar] [CrossRef]
- Maachi, M.; Piéroni, L.; Bruckert. E.; Jardel. C.; Fellahi, S.; Hainque, B.; Capeau, J.; Bastard, J.P. Systemic low-grade inflammation is related to both circulating and adipose tissue TNFalpha, leptin and IL-6 levels in obese women. Int J Obes Relat Metab Disord. 2004, 28, 993–997. [Google Scholar] [CrossRef]
- Aladhami, A.K.; Unger, C.A.; Ennis, S.L.; Altomare, D.; Ji, H.; Hope, M.C. 3rd.; Velázquez, K.T.; Enos, R.T. Macrophage tumor necrosis factor-alpha deletion does not protect against obesity-associated metabolic dysfunction. FASEB J. 2021, 35, e21665. [Google Scholar] [CrossRef]
- Perticone, M.; Zito, R.; Miceli, S.; Pinto, A.; Suraci, E.; Greco, M.; Gigliotti, S.; Hribal, M.L.; Corrao, S.; Sesti, G.; Perticone, F. Immunity, Inflammation and Heart Failure: Their Role on Cardiac Function and Iron Status. Front Immunol. 2019, 10, 2315. [Google Scholar] [CrossRef] [PubMed]
- Raggi, P.; Genest, J.; Giles, J.T.; Rayner, K.J.; Dwivedi, G.; Beanlands, R.S.; Gupta, M. Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions. Atherosclerosis. 2018, 276, 98–108. [Google Scholar] [CrossRef] [PubMed]
- Ruparelia, N.; Choudhury, R. Inflammation and atherosclerosis: what is on the horizon? Heart. 2020, 106, 80–85. [Google Scholar] [CrossRef] [PubMed]
- Tedgui, A.; Mallat, Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006, 86, 515–581. [Google Scholar] [CrossRef] [PubMed]
- Wolf, D.; Ley, K. Immunity and Inflammation in Atherosclerosis. Circ Res. 2019, 124, 315–327. [Google Scholar] [CrossRef]
- Corona, G.; Rastrelli, G.; Monami, M.; Guay, A.; Buvat, J.; Sforza, A.; Forti, G.; Mannucci, E.; Maggi, M. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol. 2011, 165, 687–701. [Google Scholar] [CrossRef]
- Webb, C.M.; McNeill, J.G.; Hayward, C.S.; de Zeigler, D.; Collins, P. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation. 1999, 100, 1690–1696. [Google Scholar] [CrossRef]
- English, K.M.; Steeds, R.P.; Jones, T.H.; Diver, M.J.; Channer, K.S. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebo-controlled study. Circulation. 2000, 102, 1906–1911. [Google Scholar] [CrossRef]
- Mathur, A.; Malkin, C.; Saeed, B.; Muthusamy, R.; Jones, T.H.; Channer, K. Long-term benefits of testosterone replacement therapy on angina threshold and atheroma in men. Eur J Endocrinol. 2009, 161, 443–449. [Google Scholar] [CrossRef]
- Foresta, C.; Di Mambro, A.; Pagano, C.; Garolla, A.; Vettor, R.; Ferlin, A. Insulin-like factor 3 as a marker of testicular function in obese men. Clin Endocrinol (Oxf). 2009, 71, 722–726. [Google Scholar] [CrossRef]
- Kumagai, H.; Miyaki, A.; Higashino, R.; Akazawa, N.; Choi, Y. Lifestyle modification-induced increase in serum testosterone and SHBG decreases arterial stiffness in overweight and obese men. Artery Res. 2014, 8, 80–87. [Google Scholar] [CrossRef]
- Kelly, D.M.; Jones, T.H. Testosterone and obesity. Obes Rev. 2015, 16, 581–606. [Google Scholar] [CrossRef] [PubMed]
- Dandona, P.; Dhindsa, S. Update: Hypogonadotropic hypogonadism in type 2 diabetes and obesity. J Clin Endocrinol Metab. 2011, 96, 2643–2651. [Google Scholar] [CrossRef] [PubMed]
- Lamm, S.; Chidakel, A.; Bansal, R. Obesity and hypogonadism. Urol Clin North Am. 2016, 43, 239–245. [Google Scholar] [CrossRef] [PubMed]
- Mulhall, J.P.; Trost, L.W.; Brannigan, R.E.; Kurtz, E.G.; Redmon, J.B.; Chiles, K.A.; Lightner, D.J.; Miner, M.M.; Murad, M.H.; Nelson, C.J.; et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018, 200, 423–432. [Google Scholar] [CrossRef]
- Hamilton, E.J.; Gianatti, E.; Strauss, B.J.; Wentworth, J.; Lim-Joon, D.; Bolton, D.; Zajac, J.D.; Grossmann, M. Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clin Endocrinol (Oxf). 2011, 74, 377–383. [Google Scholar] [CrossRef]
- Isidori, A.M.; Caprio, M.; Strollo, F.; Moretti, C.; Frajese, G.; Isidori, A.; Fabbri, A. Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. J Clin Endocrinol Metab. 1999, 84, 3673–3680. [Google Scholar]
- Lafontan, M. Fat cells: afferent and efferent messages define new approaches to treat obesity. Annu Rev Pharmacol Toxicol. 2005, 45, 119–146. [Google Scholar] [CrossRef]
- Cinti, S.; Mitchell, G.; Barbatelli, G.; Murano, I.; Ceresi, E.; Faloia, E.; Wang, S.; Fortier, M.; Greenberg, A.S.; Obin, M.S. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res. 2005, 46, 2347–2355. [Google Scholar] [CrossRef]
- Karastergiou, K.; Mohamed-Ali, V. The autocrine and paracrine roles of adipokines. Mol Cell Endocrinol. 2010, 318, 69–78. [Google Scholar] [CrossRef]
- Ellulu, M.S.; Khaza'ai, H.; Abed, Y.; Rahmat, A.; Ismail, P.; Ranneh, Y. Role of fish oil in human health and possible mechanism to reduce the inflammation. Inflammopharmacology. 2015, 23, 79–89. [Google Scholar] [CrossRef] [PubMed]
- Smith, J.C.; Bennett, S.; Evans, L.M.; Kynaston, H.G.; Parmar, M.; Mason, M.D.; Cockcroft, J.R.; Scanlon, M.F.; Davies, J.S. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab. 2001, 86, 4261–4267. [Google Scholar] [CrossRef] [PubMed]
| Variables | Normal Weight, Hypertensive and Overweight Hypertensive Subjects | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| HT vs. NC | OHT vs. NC | OHT vs. HT | |||||||
| NC | HT | P-value | NC | OHT | P-value | HT | OHT | P-value | |
| Number of subjects (n) | 98 | 97 | - | 98 | 97 | - | 97 | 97 | - |
| Sex (male) | 98 | 97 | - | 98 | 97 | - | 97 | 97 | - |
| Age (years) | 55.37± 2.86 |
55.35± 2.82 |
NS | 55.37± 2.86 |
55.36± 2.78 |
NS | 55.35± 2.82 |
55.36± 2.78 |
NS |
| Age range (years) | 51-60 | 51-60 | - | 51-60 | 51-60 | - | 51-60 | 51-60 | - |
| BMI (kg/m2) | 24.04± 0.60 |
24.03± 0.61 |
NS | 24.04± 0.60 |
29.06± 0.58 |
<0.0001 | 24.03± 0.61 |
29.06± 0.58 |
<0.0001 |
| BMI range (kg/m2) | 23-24.9 | 23-24.9 | - | 23-24.9 | 28-29.9 | - | 23-24.9 | 28-29.9 | - |
| TC (mg/dl) | 177.06± 9.49 |
189.32± 13.65 |
<0.0001 | 177.06± 9.49 |
194.16± 12.37 |
<0.0001 | 189.32± 13.65 |
194.16± 12.37 |
<0.01 |
| FBG (mg/dL) | 97.98± 6.86 |
97.64± 6.24 |
NS | 97.98± 6.86 |
98.41± 7.11 |
NS | 97.64± 6.24 |
98.41± 7.11 |
NS |
| IL-6 ((pg/ml) | 6.46± 6.23 |
7.88± 6.03 |
NS | 6.46± 6.23 |
10.90± 8.63 |
<0.0001 | 7.88± 6.03 |
10.90± 8.63 |
<0.004 |
| Hp (ng/mL) | 11.44± 5.76 |
10.91± 5.49 |
NS | 11.44± 5.76 |
11.17± 5.46 |
NS | 10.91± 5.49 |
11.17± 5.46 |
NS |
| TNF-α (pg/ml) | 4.69± 2.10 |
8.25± 3.57 |
<0.0001 | 4.69± 2.10 |
11.71± 5.07 |
<0.0001 | 8.25± 3.57 |
11.71± 5.07 |
<0.0001 |
| ST (mg/dl) | 417.96± 175.28 |
378.09± 179.41 |
NS | 417.96± 175.28 |
345.36± 155.80 |
<0.002 | 378.09± 179.41 |
345.36± 155.80 |
NS |
| Lep (ng/mL) | 5.75± 2.27 |
10.02± 6.35 |
<0.0001 | 5.75± 2.27 |
13.13± 7.26 |
<0.0001 | 10.02± 6.35 |
13.13± 7.26 |
<0.001 |
| Variables | Normal Weight Hypertensive and Overweight Hypertensive Subjects |
P-value |
||
|---|---|---|---|---|
| NC | HT | OHT | ||
| Number of subjects (n) | 98 | 97 | 97 | - |
| Sex (male) | 98 | 97 | 97 | - |
| Age (years) | 55.37±2.86 | 55.35±2.82 | 55.36±2.78 | NS |
| Age range (years) | 51-60 | 51-60 | 51-60 | - |
| BMI (kg/m2) | 24.04±0.60 | 24.03±0.61 | 29.06±0.58 | <0.001 |
| BMI range (kg/m2) | 23-24.9 | 23-24.9 | 28-29.9 | - |
| TC (mg/dl) | 177.06±9.49 | 189.32±13.65 | 194.16±12.37 | <0.001 |
| FBG (mg/dL) | 97.98±6.86 | 97.64±6.24 | 98.41±7.11 | NS |
| IL-6 ((pg/ml) | 6.46±6.23 | 7.88±6.03 | 10.90±8.63 | <0.001 |
| Hp (ng/mL) | 11.44±5.76 | 10.91±5.49 | 11.17±5.46 | NS |
| TNF-α (pg/ml) | 4.69±2.10 | 8.25±3.57 | 11.71±5.07 | <0.001 |
| ST (mg/dl) | 417.96±175.28 | 378.09±179.41 | 345.36±155.80 | <0.05 |
| Lep (ng/mL) | 5.75±2.27 | 10.02±6.35 | 13.13±7.26 | <0.001 |
| Variables | Coefficient of Determination (R2) and Significance Levels for Association of Variables in Normal Weight Control and Hypertensive and Overweight-Related Hypertensive Middle-Aged Men | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lep | TNF- α | ST | IL-6 | |||||||||
| NC (n: 98) |
HT (n:97) | OHT (n:97) | NC (n:98) | HT (n:97) | OHT (n:97) | NC (n: 98) |
HT (n:97) | OHT (n:97) | NC (n:98) | HT (n:97) | OHT (n:97) | |
| TNF-α | 0.62*4 |
0.69*4 |
0.91*4 | - | - | - | 0.39*4 | 0.48*4 | 0.37*4 | 0.38*4 | 0.50*4 | 0.63 *4 |
| ST | 0.34*4 |
0.27*4 |
0.34*4 | 0.39*4 | 0.48*4 | 0.37*4 | - | - | - | 0.11*4 | 0.21*4 | 0.18 *4 |
| IL-6 | 0.37*4 |
0.72*4 |
0.73*4 | 0.38*4 | 0.50*4 | 0.63*4 | 0.11*2 | 0.21*4 | 0.18*4 | - | - | - |
| Hp | 0.006 | 0.22 | 0.009 | 0.006 | 0.02 | 0.002 | 0.000 | 0.000 | 0.004 | 0.004 | 0.02 | 0.01 |
| TC | 0.07*2 |
0.09*2 |
0.12*3 | 0.12*3 | 0.13*3 | 0.11*4 | 0.09*2 | 0.010 | 0.01 | 0.14*3 | 0.11*3 | 0.07*2 |
| FBG |
0.001 |
0.005 |
0.02 |
0.000 |
0.02 |
0.01 |
0.001 |
0.002 |
0.000 |
0.02 |
0.01 |
0.01 |
| Lep | - | - | - |
0.62*4 |
0.69*4 |
0.91*4 |
0.34*4 |
0.27*4 |
0.34*4 |
0.37*4 |
0.72*4 |
0.73*4 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
